H. de Lavallade

S. Brett, K. Rezvani, D. Marin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

K. Rezvani, D. Marin, J. Goldman, 2008, Blood.

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

D. Marin, T. Holyoake, J. Goldman, 2010, Haematologica.

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

D. Marin, J. Goldman, D. Milojković, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational study

L. Taheri, H. de Lavallade, V. Metaxa, 2021, Annals of Hematology.

Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

K. Rezvani, C. Harrison, D. Mclornan, 2021, British journal of haematology.

G. Mufti, H. de Lavallade, P. Muus, 2019, Blood advances.

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.

G. Mufti, S. Jackson, D. Mclornan, 2019, The Lancet. Haematology.

What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

H. de Lavallade, D. Radia, P. Harrington, 2020, Expert review of hematology.

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis

D. Marin, J. Goldman, D. Milojković, 2008, British journal of haematology.

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.

G. Rosti, J. Cortes, M. Deininger, 2021, Blood.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

D. Marin, J. Goldman, P. Mehta, 2008, Blood.

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

K. Rezvani, S. Parmar, E. Shpall, 2014, Blood.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2019, The Lancet. Haematology.

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study

G. Mufti, D. Mclornan, F. Dazzi, 2021, Blood Cancer Journal.

Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience

G. Mufti, D. Mclornan, A. Kassim, 2019, Front. Oncol..

The Role of Early Molecular Response in the Management of Chronic Phase CML

H. de Lavallade, A. Kizilors, P. Harrington, 2017, Current Hematologic Malignancy Reports.

Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

P. Ljungman, C. Cordonnier, D. Engelhard, 2019, The Lancet. Infectious diseases.

Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.

G. Mufti, D. Mclornan, O. Malik, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Novel developments in chronic myeloid leukaemia

H. de Lavallade, P. Harrington, 2021, Current opinion in hematology.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2017, The Lancet. Haematology.

Early and late‐onset veno‐occlusive disease/sinusoidal syndrome post allogeneic stem cell transplantation – a real‐world UK experience

G. Mufti, H. de Lavallade, A. Pagliuca, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

C. Craddock, C. Yap, J. Byrne, 2019, Blood.

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).

P. Ljungman, C. Cordonnier, D. Engelhard, 2019, The Lancet. Infectious diseases.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

G. Mufti, D. Mclornan, H. de Lavallade, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation.

D. Blaise, M. Mohty, P. Viens, 2010, Experimental hematology.

Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience

G. Mufti, R. Benjamin, S. Norton, 2020, British journal of haematology.

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

M. Malim, D. Mclornan, C. Graham, 2021, British journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

M. Malim, C. Harrison, D. Mclornan, 2021, Leukemia.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

G. Mufti, R. Ireland, H. de Lavallade, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

G. Mufti, D. Mclornan, H. de Lavallade, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

K. Rezvani, D. Marin, E. Shpall, 2013, Blood.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

D. Marin, J. Goldman, L. Foroni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.

C. Craddock, C. Yap, J. Byrne, 2021, The Lancet. Haematology.

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice

H. de Lavallade, A. Kizilors, 2016, EMJ Oncology.

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Jaspal Kaeda, D. Marin, J. Goldman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia

A. Mead, J. Byrne, M. Copland, 2020, British journal of haematology.

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

D. Blaise, A. Nagler, M. Mohty, 2008, Haematologica.

The role of a critical care outreach service in the management of patients with haematological malignancy

G. Mufti, G. Auzinger, L. Taheri, 2019, Journal of the Intensive Care Society.

Alemtuzumab vs anti‐thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning

G. Mufti, S. Chevret, M. Robin, 2018, European journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML

M. Malim, D. Mclornan, C. Graham, 2021, medRxiv.

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag

G. Mufti, D. Consonni, R. Ireland, 2019, Haematologica.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients

M. Malim, D. Mclornan, K. Doores, 2021, Cancer Cell.

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

G. Mufti, D. Mclornan, H. de Lavallade, 2019, Bone Marrow Transplantation.

Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Clinical lymphoma & myeloma.

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.

D. Blaise, M. Mohty, H. de Lavallade, 2006, Haematologica.

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

D. Mclornan, H. de Lavallade, K. Raj, 2022, British journal of haematology.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

G. Mufti, R. Marcus, R. Ireland, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer?

K. Rezvani, H. de Lavallade, 2011, Expert review of vaccines.

Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin.

D. Blaise, C. Chabannon, H. de Lavallade, 2009, Blood.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients

M. Malim, D. Mclornan, K. Doores, 2021, Cancer Cell.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

C. Craddock, C. Yap, K. Brock, 2021, Blood.

CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial.

G. Rosti, J. Cortes, M. Deininger, 2022, Clinical lymphoma, myeloma & leukemia.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

M. Malim, D. Mclornan, K. Doores, 2022, Blood Cancer Journal.

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

M. Malim, C. Harrison, D. Mclornan, 2022, Blood Advances.

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

G. Rosti, J. Cortes, M. Deininger, 2022, Blood.

Anti‐type M phospholipase A2 receptor antibody‐positive membranous nephropathy as a part of multi‐system autoimmune syndrome post‐allogeneic stem cell transplantation

G. Mufti, D. Mclornan, H. de Lavallade, 2018, Internal medicine journal.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

G. Mufti, D. Mclornan, H. de Lavallade, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

G. Rosti, M. Deininger, C. Chuah, 2022, Blood.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

K. Rezvani, D. Marin, J. Goldman, 2011, Haematologica.